Summary
Global Markets Direct’s, ‘INSYS Therapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the INSYS Therapeutics, Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by INSYS Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of INSYS Therapeutics, Inc.
- The report provides overview of INSYS Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses INSYS Therapeutics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features INSYS Therapeutics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate INSYS Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for INSYS Therapeutics, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding INSYS Therapeutics, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
INSYS Therapeutics, Inc. Snapshot 5
INSYS Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
INSYS Therapeutics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
INSYS Therapeutics, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
INSYS Therapeutics, Inc. - Pipeline Products Glance 12
INSYS Therapeutics, Inc. - Late Stage Pipeline Products 12
Pre-Registration Products/Combination Treatment Modalities 12
Phase III Products/Combination Treatment Modalities 13
INSYS Therapeutics, Inc. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
INSYS Therapeutics, Inc. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
INSYS Therapeutics, Inc. - Drug Profiles 17
dronabinol 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
buprenorphine hydrochloride 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Cannabidiol 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
(buprenorphine hydrochloride + naloxone hydrochloride) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
naloxone hydrochloride 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ondansetron hydrochloride 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
paclitaxel 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
cetirizine hydrochloride + cromolyn sodium 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
diclofenac sodium 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ketorolac tromethamine 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
sildenafil citrate 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
INSYS Therapeutics, Inc. - Pipeline Analysis 30
INSYS Therapeutics, Inc. - Pipeline Products by Target 30
INSYS Therapeutics, Inc. - Pipeline Products by Route of Administration 32
INSYS Therapeutics, Inc. - Pipeline Products by Molecule Type 33
INSYS Therapeutics, Inc. - Pipeline Products by Mechanism of Action 34
INSYS Therapeutics, Inc. - Recent Pipeline Updates 35
INSYS Therapeutics, Inc. - Dormant Projects 38
INSYS Therapeutics, Inc. - Discontinued Pipeline Products 39
Discontinued Pipeline Product Profiles 39
Monoclonal Antibody Conjugate to Target Mesothelin for Oncology 39
INSYS Therapeutics, Inc. - Company Statement 40
INSYS Therapeutics, Inc. - Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45
List of Tables
INSYS Therapeutics, Inc., Key Information 5
INSYS Therapeutics, Inc., Key Facts 5
INSYS Therapeutics, Inc. - Pipeline by Indication, 2016 7
INSYS Therapeutics, Inc. - Pipeline by Stage of Development, 2016 9
INSYS Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016 10
INSYS Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016 11
INSYS Therapeutics, Inc. - Pre-Registration, 2016 12
INSYS Therapeutics, Inc. - Phase III, 2016 13
INSYS Therapeutics, Inc. - Phase II, 2016 14
INSYS Therapeutics, Inc. - Phase I, 2016 15
INSYS Therapeutics, Inc. - Preclinical, 2016 16
INSYS Therapeutics, Inc. - Pipeline by Target, 2016 30
INSYS Therapeutics, Inc. - Pipeline by Route of Administration, 2016 32
INSYS Therapeutics, Inc. - Pipeline by Molecule Type, 2016 33
INSYS Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016 34
INSYS Therapeutics, Inc. - Recent Pipeline Updates, 2016 35
INSYS Therapeutics, Inc. - Dormant Developmental Projects,2016 38
INSYS Therapeutics, Inc. - Discontinued Pipeline Products, 2016 39
INSYS Therapeutics, Inc., Other Locations 43
INSYS Therapeutics, Inc., Subsidiaries 43
List of Figures
INSYS Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016 7
INSYS Therapeutics, Inc. - Pipeline by Stage of Development, 2016 9
INSYS Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016 10
INSYS Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016 11
INSYS Therapeutics, Inc. - Pipeline by Top 10 Target, 2016 30
INSYS Therapeutics, Inc. - Pipeline by Route of Administration, 2016 32
INSYS Therapeutics, Inc. - Pipeline by Molecule Type, 2016 33
INSYS Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 34
